Loading
RNA drugs that copy themselves inside the cell, or are made as a loop so they last longer. Both aim to get more protein from a smaller dose.
Self-amplifying RNA carries a replicase, so a small dose produces protein for days; circular RNA has no free ends, resists exonucleases, and is translated for longer than linear mRNA. Both are being applied to cancer vaccines and to in vivo expression of antibodies, cytokines, and CAR constructs. Oncology work is early phase and largely company-reported; the approved precedent is a self-amplifying COVID-19 vaccine, not a cancer therapy.
An alphavirus-derived replicase amplifies the transcript in the cytoplasm (saRNA), or a permuted intron-exon strategy circularises the RNA to extend its half-life; both are delivered in lipid nanoparticles.
Query for this technology: (TITLE:"Self-amplifying and circular RNA therapeutics" OR ABSTRACT:"Self-amplifying and circular RNA therapeutics") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Self-amplifying and circular RNA therapeutics, not a curated reading list.
Shares In vivo CAR-T, Radical oncology: what could change the war by 2035, Personalised neoantigen (mRNA) vaccines and the tags frontier, promising.
Shares In vivo CAR-T, Radical oncology: what could change the war by 2035 and the tags frontier, promising.
Shares Radical oncology: what could change the war by 2035, Personalised neoantigen (mRNA) vaccines and the tags frontier, promising.
Shares Radical oncology: what could change the war by 2035 and the tags frontier, promising.
Shares Radical oncology: what could change the war by 2035 and the tags frontier, promising.
Shares Radical oncology: what could change the war by 2035 and the tags frontier, promising.
Shares Radical oncology: what could change the war by 2035 and the tags frontier, promising.
Shares Radical oncology: what could change the war by 2035 and the tags frontier, promising.